Role of osteopontin in predicting short term outcome in acute STEMI.

Background: ST segment elevation myocardial infarction (SETMI) represents a very serious cardiac condition where Primary percutaneous coronary intervention (PPCI) is the most effective treatment strategy adopted nowadays. However major adverse cardiovascular events (MACE) are representing a challenge for prediction and management. Osteopontin (OPN) is a member of the small integrin-binding ligand n-linked glycoprotein that is involved in ischemic vascular pathologies including myocardial infarction. Aim: Our study aims to evaluate the role of osteopontin in predicting short term outcome in acute STEMI treated with primary PCI regarding changes in left ventricular systolic function and occurrence of 5-point MACE. Patients and methods: 404 participants were enrolled in our study. they were divided into two groups: group 1 (n= 202) who presented with STEMI and treated with PPCI, and group 2 (n= 202) age and sex matched with normal coronary angiography as a control group. ECG, Echocardiography, laboratory investigations including serum osteopontin on admission were performed. In-hospital MACE, angiographic and PPCI data were recorded. A follow up period after one and six months to 5-point MACE and follow up echocardiography of the patients were the end point of our study. Results: the mean OPN level was significantly higher among group 1 (11.9 ± 7.19 ng/ml) than group 2 (2.15 ± 0.47 ng/ml), the difference was statistically significant (P=0.001).